CAR T-cell therapy to treat multiple myeloma: Current state and future directions

This review explores chimeric antigen receptor (CAR) T-cell design, FDA indications, challenges, and future directions in MM care. CAR T-cell therapy is a breakthrough in treating relapsed/refractory multiple myeloma (MM), offering a one-time treatment alternative to ongoing drug regimens. Current therapies target B-cell maturation antigen, with new targets like GPRC5D under study. While effective, CAR T-cell therapy carries risks such as cytokine release syndrome and neurotoxicity. This review explores CAR T-cell design, FDA indications, challenges, and future directions in MM care.